(19)
(11) EP 4 217 385 A2

(12)

(88) Date of publication A3:
23.06.2022

(43) Date of publication:
02.08.2023 Bulletin 2023/31

(21) Application number: 21806447.5

(22) Date of filing: 28.09.2021
(51) International Patent Classification (IPC): 
C07K 16/10(2006.01)
A61P 31/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/505; A61K 2039/507; A61K 2039/545; C07K 16/10; C07K 2317/21; C07K 2317/76; C07K 2317/92; C07K 2317/526; C07K 2317/71; A61P 31/14
(86) International application number:
PCT/US2021/052481
(87) International publication number:
WO 2022/067269 (31.03.2022 Gazette 2022/13)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 28.09.2020 US 202063084501 P
09.11.2020 US 202063111435 P
11.11.2020 US 202063112505 P
30.11.2020 US 202063119545 P
13.01.2021 US 202163137112 P
02.04.2021 US 202163170356 P

(71) Applicants:
  • VIR Biotechnology, Inc.
    San Francisco, CA 94158 (US)
  • Humabs Biomed SA
    6500 Bellinzona (CH)

(72) Inventors:
  • CORTI, Davide
    6500 Bellinzona (CH)
  • DE MARCO, Anna
    6500 Bellinzona (CH)
  • PIZZUTO, Matteo Samuele
    6500 Bellinzona (CH)
  • GUARINO, Barbara
    6500 Bellinzona (CH)
  • LEMPP, Florian A.
    San Francisco, California 94158 (US)
  • CHEN, Alex
    San Francisco, California 94158 (US)
  • ROSEN, Laura
    San Francisco, California 94158 (US)

(74) Representative: Graf von Stosch Patentanwaltsgesellschaft mbH 
Prinzregentenstraße 22
80538 München
80538 München (DE)

   


(54) ANTIBODIES AGAINST SARS-COV-2